Stock Report

All about this stock under one free report Last Updated: 29-Aug-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Clear All

Venus Remedies Peer Comparison

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

NSE: VENUSREM | BSE: 526953

₹1,626.70

up-down-arrow ₹28.60 (1.79%)

As on 28-Aug-2026IST

Market cap

info icon

₹2,172 Cr

Revenue (TTM)

info icon

₹811 Cr

P/E Ratio

info icon

18.7

P/B Ratio

info icon

3.2

Div. Yield

info icon

0.6 %

Edit peer-selector-edit
Venus Remedies Pfizer Caplin Point Lab Eris Lifesciences Astrazeneca Pharma
Market cap (₹ Cr)
 2,172 21,501 19,125 18,253 17,766
Revenue (₹ Cr)
 811 2,570 2,287 3,230 2,432
Net Profit (₹ Cr)
 116.17 735.15 678.07 666.92 169.62
Net Margin (%)
 14.11 26.88 28.10 20.60 6.90
RoE (%)
 18.47 19.16 19.73 18.75 20.76
Price to Earnings
 18.70 29.25 28.74 28.35 104.74
Price-To-Book
 3.16 4.88 5.08 4.51 19.65

Income Statement (₹ Cr)

Venus Remedies Pfizer Caplin Point Lab Eris Lifesciences Astrazeneca Pharma
Operating Revenue arrow
769.60 2,519.65 1,937.47 2,893.64 2,275.58
Total Income arrow
782.18 2,707.60 2,033.90 2,912.00 2,304.07
Total Expenditure arrow
622.32 1,615.47 1,290.54 1,876.44 2,013.55
EBITDA arrow
147.28 904.18 646.93 1,017.20 262.03
Depreciation arrow
25.67 57.73 65.96 315.46 28.58
EBIT arrow
121.61 846.45 580.97 701.74 233.45
Interest arrow
0.04 9.57 0.61 231.29 4.49
Other Income arrow
12.58 187.95 96.43 18.36 28.49
Exceptional Items arrow
9.91 -49.16 -- -- -5.25
Profit before Tax arrow
134.15 975.67 676.78 488.87 252.20
Provision for Tax arrow
31.36 253.24 135.69 114.20 64.68
Profit after Tax arrow
102.79 722.43 541.09 374.67 187.52

Liabilities (₹ Cr)

Venus Remedies Pfizer Caplin Point Lab Eris Lifesciences Astrazeneca Pharma
Shareholder's Funds arrow
663.75 4,202.90 2,850.49 2,854.36 872.79
Minority Interest arrow
-- -- 35.90 417.40 --
Non-Current Liabilities arrow
28.20 19.19 13.24 2,100.97 394.49
Current Liabilities arrow
161.76 627.48 305.99 1,489.55 1,109.50
Total Liabilities arrow
853.70 4,921.88 3,207.85 6,862.28 2,414.58

Assets (₹ Cr)

Venus Remedies Pfizer Caplin Point Lab Eris Lifesciences Astrazeneca Pharma
Non-Current Assets arrow
458.50 1,046.35 1,071.67 5,531.13 509.16
Current Assets arrow
395.20 3,803.22 2,133.95 1,331.15 1,859.88
Total Assets arrow
853.70 4,921.88 3,207.85 6,862.28 2,414.58
Total Debt* arrow
0.00 2.50 0.55 2,421.66 0.00
Net Current Assets arrow
233.45 3,175.74 1,827.96 -158.40 750.38
Contingent Liabilities arrow
19.86 370.49 0.64 64.29 121.23

Cashflow (₹ Cr)

Venus Remedies Pfizer Caplin Point Lab Eris Lifesciences Astrazeneca Pharma
Cash From Operating Activities arrow
155.77 967.57 432.37 1,065.01 -15.14
Cash Flow from Investing Activities arrow
-181.57 -561.67 -334.73 -79.97 18.69
Cash from Financing Activities arrow
-3.12 -798.31 -38.32 -881.32 -91.97
Net Cash Inflow / Outflow arrow
-28.91 -392.41 59.32 103.72 -88.42

Ratios

Profitability Ratios

 Venus Remedies Pfizer Caplin Point Lab Eris Lifesciences Astrazeneca Pharma
ROCE (%) arrow
21.88 23.39 26.22 13.59 31.24
ROE (%) arrow
16.79 17.16 21.72 13.81 23.02
ROA (%) arrow
13.10 14.91 18.37 5.48 8.90
EBIT Margin (%) arrow
20.77 43.34 38.37 35.79 12.77
Net Margin (%) arrow
13.14 26.68 26.60 12.87 8.14
Cash Profit Margin (%) arrow
16.69 29.72 31.33 23.22 9.47

Growth Ratios

 Venus Remedies Pfizer Caplin Point Lab Eris Lifesciences Astrazeneca Pharma
Revenue Growth (%) arrow
17.88 10.45 14.37 44.02 32.59
EBIT Growth (%) arrow
89.22 19.68 20.21 48.22 -1.38
Net Profit Growth (%) arrow
126.83 -5.88 17.27 -5.65 62.02
EPS Growth (%) arrow
126.83 -5.88 17.25 -10.39 62.02
Book Value Growth (%) arrow
18.33 -0.34 23.77 10.19 13.51

Valuation Ratios

 Venus Remedies Pfizer Caplin Point Lab Eris Lifesciences Astrazeneca Pharma
Price / Earnings arrow
10.74 29.89 28.38 54.83 103.45
Price / Book Value arrow
1.66 5.14 5.52 6.78 22.39
Dividend Yield (%) arrow
1.21 1.59 0.30 0.52 0.46
EV/EBITDA arrow
6.72 16.93 19.78 20.75 65.23
Market Cap (₹ Cr) arrow
1,103.60 21,592.90 15,219.80 19,292.77 19,398.64

Solvency Ratios

 Venus Remedies Pfizer Caplin Point Lab Eris Lifesciences Astrazeneca Pharma
Debt to Equity arrow
0.00 0.00 0.00 0.85 0.00
Short term debt to equity ratio arrow
0.00 0.00 0.00 0.14 --
Current Ratio arrow
2.44 6.06 6.97 0.89 1.68
Quick Ratio arrow
1.64 5.31 5.88 0.67 0.75
Interest Coverage arrow
3,656.40 102.95 1,110.48 3.11 57.17

Operating Efficiency Ratios

 Venus Remedies Pfizer Caplin Point Lab Eris Lifesciences Astrazeneca Pharma
Debtors to sales (%) arrow
13.42 7.22 32.65 15.85 9.39
Asset Turnover arrow
0.98 0.54 0.66 0.43 1.08
Receivable days arrow
51.10 26.06 110.70 54.07 31.88
Inventory Days arrow
54.51 65.95 65.86 32.16 126.03
Payable days arrow
96.77 81.01 105.88 140.91 163.79
Cash Conversion Cycle arrow
8.84 11.00 70.68 -54.68 -5.88
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...